Clearmind Medicine (FRA:CWY0) Stock Based Compensation: €1.48 Mil (TTM As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:CWY0 Clearmind Medicine Inc FRA:CWY0
22 GF Score
Price €22.56
! 1 Warning Sign
View Full Analysis

What is Clearmind Medicine Stock Based Compensation?

Clearmind Medicine FRA:CWY0 22 Stock Based Compensation is €1.48 Mil as of Apr. 2026. GuruFocus rates FRA:CWY0 with a GF Score™ of 22/100. The stock has 1 warning sign investors should review.

Clearmind Medicine's Stock Based Compensation for the three months ended in Apr. 2026 was €0.11 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Apr. 2026 was €1.48 Mil.

Clearmind Medicine Stock Based Compensation Related Terms

Clearmind Medicine Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Clearmind Medicine's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clearmind Medicine Stock Based Compensation Chart

Clearmind Medicine Annual Data
Trend Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24 Oct25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only 0.53 1.23 0.79 0.92 0.69

Clearmind Medicine Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.21 0.07 0.10 1.20 0.11
FRA:CWY0
22GF Score
Clearmind Medicine Inc FRA:CWY0
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Clearmind Medicine Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.48 Mil.

What does a Stock Based Compensation of €1.48 Mil mean?
Clearmind Medicine (FRA:CWY0) has a Stock Based Compensation of €1.48 Mil as of Apr. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Clearmind Medicine and its competitors.
Is Clearmind Medicine's Stock Based Compensation too high?
Clearmind Medicine's current Stock Based Compensation is €1.48 Mil. Overall, Clearmind Medicine has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Clearmind Medicine's Stock Based Compensation compare to SLXN and OGEN?
Clearmind Medicine's Stock Based Compensation of €1.48 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Clearmind Medicine and its competitors. Clearmind Medicine's current Stock Based Compensation is €1.48 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clearmind Medicine stock overvalued right now?
Clearmind Medicine (FRA:CWY0) has a current Stock Based Compensation of €1.48 Mil. The current Stock Based Compensation is €1.48 Mil. Clearmind Medicine's overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Clearmind Medicine (FRA:CWY0), the current Stock Based Compensation is €1.48 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Clearmind Medicine Business Description

Other Exchanges CMND:USA
Address 101-1220 West 6th Avenue, Vancouver, BC, CAN, V6H1A5
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.
22GF Score

Get the complete analysis for FRA:CWY0

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€22.56
Price